Hyperhomocysteinemia and cardiovascular risk: Effect of vitamin supplementation in risk reduction

Current Clinical Pharmacology

Volumn 5, Issue 1, 2010, Pages 30-36

  Ciaccio, Marcello ^a   Bellia, Chiara ^a  

^a UNIVERSITY OF PALERMO   (Italy)

Author keywords

B vitamins; Cardiovascular disease; Folate; Homocysteine; MTHFR

Indexed keywords

5 METHYLTETRAHYDROFOLIC ACID; CYANOCOBALAMIN; CYSTATHIONINE BETA SYNTHASE; FOLIC ACID; HOMOCYSTEINE; LOW DENSITY LIPOPROTEIN; METHIONINE; METHIONINE SYNTHASE REDUCTASE; PYRIDOXINE; REACTIVE OXYGEN METABOLITE;

AMINO ACID BLOOD LEVEL; AMINO ACID METABOLISM; ATHEROSCLEROSIS; BRAIN INFARCTION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DRUG DOSE COMPARISON; FOLLOW UP; GENE MUTATION; GENETIC LINKAGE; HEART INFARCTION; HEREDITY; HUMAN; HYPERHOMOCYSTEINEMIA; ISCHEMIC HEART DISEASE; OUTCOME ASSESSMENT; OXIDATION; PATHOPHYSIOLOGY; POINT MUTATION; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; THROMBOSIS; VASCULAR DISEASE; VITAMIN SUPPLEMENTATION;

ANIMALS; CARDIOVASCULAR DISEASES; FOLIC ACID; HUMANS; HYPERHOMOCYSTEINEMIA; RISK FACTORS; RISK REDUCTION BEHAVIOR; VITAMIN B 12; VITAMIN B 6; VITAMIN B COMPLEX;

EID: 77950787113     PISSN: 15748847     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488410790410551     Document Type: Review

References (62)

1. Christensen B, Refsum H, Vintermyr O, Ueland PM. Homocysteine export from cells cultured in the presence of physiological or superfluous levels of methionine: methionine loading of non-transformed, transformed, proliferating, and quiescent cells in culture. J Cell Physiol 1991; 146: 52-62.
2. Ueland PM. Homocysteine species as components of plasma redox thiol status. Clin Chem 1995; 41: 340-342
3. Refsum H, Fiskerstrand T, Guttormsen AB, et al. Assessment of homocysteine status. J Inherit Metab Dis 1997; 20: 286-294
4. Refsum H, Smith AD, Ueland PM, et al. Facts and recommendation about total homocysteine determinations: an expert opinion. Clin Chem 2004; 50: 3-32.
5. Rosenblatt DS, Cooper BA. Inherited disorders of vitamin B12 utilization. Bioessays 1990; 12: 331-334
6. Kang SS, Zhou J, Wong PWK, et al. Intermediate homocysteinemia: a thermolabile variant of methylentethrahydrofolate reductase. Am J Hum Genet 1988; 43: 414-421
7. Kang SS, Wong PWK, Susmano A, et al. Thermolabile methylenetetrahydrofolate reductase: an inherited risk factor for coronaru artery disease. Am J Hum Genet 1991; 48: 536-545
8. Brattstrom L, Wilcken DE, Ohrvik J, Brudin L. Common methylenetetrahydrofolate reductase gene mutation leads to hyperhomocys-teinemia but not to vascular disease: the result of a meta-analysis. Circulation 1998; 98: 2520-2526
9. Jacques PF, Bostom AG, Williams RR, et al. Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations. Circulation 1996; 93: 7-9.
10. Dudman NP, Wilcken DE, Wang J, Lynch JF, Macey D, Lundberg P. Disordered methionine/homocysteine metabolism in premature vascular disease. Its occurrence, cofactor therapy, and enzymology. Arterioscler Thromb 1993; 13: 1253-1260
11. Kang SS, Wong PW, Norusis M. Homocysteinemia due to folate deficiency. Metabolism 1987; 36: 458-462
12. Stabler SP, Marcell PD, Podell ER, Allen RH, Savage DG, Lindenbaum J. Elevation of total homocysteine in the serum of patients with cobalamin or folate deficiency detected by capillary gas chromatography-mass spectrometry. J Clin Invest 1988; 81: 466-474
13. Lindenbaum J, Healton EB, Savage DG, et al. Neuropsychiatric disorders caused by cobalamin deficiency in the absence of anemia or macrocytosis. N Engl J Med 1988; 318: 1720-1728
14. Klee GG. Cobalamin and folate evaluation: measurement of methylmalonic acid and homocysteine vs vitamin B(12) and folate. Clin Chem 2000; 46: 1277-1283
15. Selhub J, Jacques PF, Wilson PW, Rush D, Rosenberg IH. Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. JAMA 1993; 270: 2693-2698
16. Bostom AG, Culleton BF. Hyperhomocysteinemia in chronic renal disease. J Am Soc Nephrol 1999; 10: 891-900.
17. Sunder-Plassmann G, Födinger M, Buchmayer H, et al. Effect of high dose folic acid therapy on hyperhomocysteinemia in hemodialysis patients: results of the Vienna multicenter study. J Am Soc Neprol 2000; 11: 1106-1116
18. McCully KS. Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis. Am J Pathol 1969; 56:111-128
19. Welch GN, Loscalzo J. Homocysteine and atherothrombosis. N Engl J Med 1998; 338: 1042-1050 (Pubitemid 128753793)
20. The Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke. A meta-analysis. JAMA 2002;288: 2015-2022
21. Wald DS, Morris JK, Law M, Wald NJ. Folic acid, homocysteine, and cardiovascular disease: judging causality in the face of inconclusive trial evidence. BMJ 2006; 333: 1114-1117
22. Austin RC, Lentz SR, Werstuck GH. Role of hyperhomocysteinemia in endothelial dysfunction and atherothrombotic disease. Cell Death Differ 2004; 11: S56-S64.
23. Hofmann MA, Lalla E, Lu Y, et al. Hyperhomocysteinemia enhances vascular inflammation and accelerates atherosclerosis in a murine model. J Clin Invest 2001; 107: 675-683
24. Zhou J, Moller J, Danielsen CC, et al. Dietary supplementation with methionine and homocysteine promotes early atherosclerosis but not plaque rupture in ApoE-deficient mice. Arterioscler Thromb Vasc Biol 2001; 21: 1470-1476
25. Tsai JC, Perrella MA, Yoshizumi M, et al. Promotion of vascular smooth muscle cell growth by homocysteine: a link to atherosclerosis. Proc Natl Acad Sci USA 1994; 91: 6369-6373
26. Postea O, Krotz F, Henger A, Keller C, Weiss N. Stereospecific and redoxsensitive increase in monocyte adhesion to endothelial cells by homocysteine. Arterioscler Thromb Vasc Biol 2006; 26: 508-513
27. Poddar R, Sivasubramanian N, DiBello PM, Robinson K, Jacobsen DW. Homocysteine induces expression and secretion of monocyte chemoattractant protein-1 and interleukin-8 in human aortic endothelial cells: implications for vascular disease. Circulation 2001;103: 2717-2723
28. Mohan IV, Jagroop IA, Mikhailidis DP, Stansby GP. Homocysteine activates platelets in vitro. Clin Appl Thromb Hemost 2008; 14: 8-18.
29. Prontera C, Martelli N, Evangelista V, et al. Homocysteine modulates the CD40/CD40L system. J Am Coll Cardiol 2007; 49: 2182-2190
30. Wilson KM, McCow RB, Leo L, et al. Prothrombotic effects of hyperhomocysteinemia and hypercholesterolemia in ApoE-deficient mice. Arterioscler Thromb Vasc Biol 2007; 27: 233-240
31. Zhang X, Li H, Jin H, Ebin Z, Brodsky S, Goligorsky MS. Effects of homocysteine on endothelial nitric oxide production. Am J Physiol Renal Physiol 2000; 279: F671-F678.
32. Topal G, Brunet A, Millanvoye E, et al. Homocysteine induces oxidative stress by uncoupling of NO synthase activity through reduction of tetrahydrobiopterin. Free Radic Biol Med 2004; 36:1532-1541
33. Au-Yeung KK, Woo CW, Sung FL, Yip JC, Siow YL. Hyperhomocysteinemia activates nuclear factor-kappaB in endothelial cells via oxidative stress. Circ Res 2004; 94: 28-36.
34. Holven KB, Holm T, Aukrust P, et al. Effect of folic acid treatment on endothelium-dependent vasodilatation and nitric oxide-derived end products in hyperhomocysteinemic subjects. Am J Med 2001;110: 536-542
35. Wei-gou Z, Shan L, Le-qing L, Hui Y, Ting F, Jian-hua Z. Vascular oxidative stress increase dendritic cell adhesion and transmigration induced by homocysteine. Cell Immunol 2009; 254: 110-116
36. Daval S, Lentz SR. ADMA and hyperhomocysteinemia. Vasc Med 2005; 10: S27-33.
37. Stuhlinger MC, Stanger O. Asymmetric dimethyl-L-arginine (ADMA): a possible link between homocyst(e)ine and endothelial dysfunction. Curr Drug Metab 2005; 6: 3-14.
38. Böger RH, Lentz SR, Bode-Böger SM, Knapp HR, Haynes WG. Elevation of asymmetrical dimethylarginine may mediate endothelial dysfunction during experimental hyperhomocyst(e)inaemia in humans. Clin Sci 2001; 100: 161-167.
39. Hong L, Fast W. Inhibition of human dimethylarginine dimethy- laminohydrolase-1 by S-nitroso-L-homocysteine and hydrogen peroxide. Analysis, quantification, and implications for hyperhomocysteinemia. J Biol Chem 2007; 282: 34684-34692
40. Dayal S, Rodionov RN, Arning E, Bottiglieri T, Kimoto M, Murry DJ, et al. Tissue-specific downregulation of dimethylarginine di-methylaminohydrolase in hyperhomocysteinemia. Am J Physiol Heart Circ Physiol 2008; 295: H816-25.
41. Wilcken DE, Wilcken B. The pathogenesis of coronary artery disease. A possible role for methionine metabolism. J Clin Invest 1976; 57: 1079-1082
42. Clarke R, Daly L, Robinson K, et al. Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med 1991; 324: 1149-1155
43. Boushey CJ, Beresford SA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA 1995; 274: 1049-1057
44. Graham IM, Daly LE, Refsum HM, et al. Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project. JAMA 1997; 277: 1775-1781
45. Nygard O, Nordrehaug JE, Refsum H, et al. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med 1997; 337: 230-236 (Pubitemid 27310438)
46. Wang T, Gona P, Larson MG, et al. Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med 2006; 355: 2631-2639
47. Evans RW, Shaten J, Hempel JD, et al. Homocyst(e)ine and risk of cardiovascular disease in the Multiple Risk Factor Intervention Trial. Arterioscler Thromb Vasc Biol 1997; 17: 1947-1953.
48. Folsom AR, Nieto FJ, McGovern PG, et al. Prospective study of coronary heart disease incidence in relation to fasting total homocysteine, related genetic polymorphism, and B vitamins. The Atherosclerosis Risk in Communities (ARIC) Study. Circulation 1998;98: 204-210
49. Ridker PM, Stampfer MJ, Rifai N. Novel risk factors for systemic atherosclerosis. A comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease. JAMA 2001; 285: 2481-2485
50. Tool JF, Malinow MR, Chambless LE, et al. Lowering homocys-teine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death. The Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA 2004; 291: 565-575
51. Bonaa KH, Njolstad I, Ueland PM, et al. Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med 2006; 354: 1578-1588
52. Lonn E, Yufsum S, Arnold MJO, et al. Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med 2006; 354: 1567-1577
53. Wang X, Qin X, Demirtas H, et al. Efficacy of folic acid supplementation in stroke prevention: a meta-analysis. Lancet 2007; 369:1876-1882
54. Khan U, Crossley C, Kalra L, et al. Homocysteine and its relationship to stroke subtypes in a UK black population. Stroke 2008; 39:2943.
55. Albert CM, Cook NR, Gaziano JM, et al. Effect of folic acid and B vitamins on risk of cardiovascular events and total mortality among women at high risk for cardiovascular disease. A randomized trial. JAMA 2008; 299: 2027-2036
56. Hodis HN, Mack WJ, Dustin L, et al. High-dose b vitamin supplementation and progression of subclinical atherosclerosis. A Randomized Controlled Trial. Stroke 2009; 40: 730-736
57. Jamison RL, Hartigan P, Kaufman JS, et al. Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renal disease. A randomized controlled trial. JAMA 2007; 298: 1163-1170
58. Mann JF, Sheridan P, McQueen MJ, et al. Homocysteine lowering with folic acid and B vitamins in people with chronic kidney disease-results of the renal Hope-2 study. Neprol Dial Transplant 2008; 23: 645-653
59. Potter K, Hankey GJ, Green DJ, et al. Homocysteine or renal impairment. Which is the real cardiovascular risk factor? Arterioscler Thromb Vasc Biol 2008; 28: 1158-1164
60. Milani RV, Lavie CJ. Homocysteine: the Rubik's cube of cardiovascular risk factors. Mayo Clin Proc 2008; 83: 1200-1202
61. Bazzano L, Reynolds K, Holder K, He J. Effect of folic acid supplementation on risk of cardiovascular disease. A meta-analysis of randomized controlled trials. JAMA 2006; 296: 2720-2726
62. Spence JD. Homocysteine-lowering therapy: a role in stroke prevention? Lancet Neurol 2007; 6: 830-838